search
Back to results

Does Atorvastatin Reduce Ischemia-Reperfusion Injury in Humans in-Vivo?

Primary Purpose

Ischemia Reperfusion Injury, Cardiovascular Disease

Status
Completed
Phase
Phase 4
Locations
Netherlands
Study Type
Interventional
Intervention
atorvastatin
Sponsored by
Radboud University Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Ischemia Reperfusion Injury focused on measuring ischemia reperfusion injury, atorvastatine, preconditioning, cardiovascular disease

Eligibility Criteria

18 Years - 50 Years (Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Male
  • Age 18-50 years
  • Informed consent
  • Physical able to perform ischemic exercise

Exclusion Criteria:

  • History of any cardiovascular disease
  • Hypertension (in supine position: systole > 140 mmHg, diastole > 90 mmHg)
  • Diabetes mellitus (fasting glucose > 7.0 mmol/L or random glucose > 11.0 mmol/L)
  • Hyperlipidaemia (fasting total cholesterol > 5.5 mmol/l)
  • Alanine-Amino-Transferase (ALAT) >90 U/L
  • Creatinine Kinase (CK) >440 U/L
  • Drug or alcohol abuse
  • Concommitant chronic use of medication
  • Administration of radioactivity in research setting during the last 5 years
  • Participation to any drug-investigation during the previous 60 days as checked with VIP check according to CRCN standard procedures

Sites / Locations

  • Radboud University Nijmegen Medical Centre

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Active Comparator

No Intervention

Arm Label

1

2

3

Arm Description

first 3 day treatment placebo and 4 weeks later three day treatment with atorvastatin 80 mg

first 3 day treatment atorvastatin 80 mg and 4 weeks later three day treatment with placebo

3 days treatment with placebo twice

Outcomes

Primary Outcome Measures

Annexin A 5 targeting in the non dominant thenar muscle after ischemic exercise, as a indicator for ischemia reperfusion injury.

Secondary Outcome Measures

workload during ischemic exercise
effect of 3-day treatment with atorvastatin 80mg daily on serum lipid levels

Full Information

First Posted
February 28, 2007
Last Updated
March 16, 2009
Sponsor
Radboud University Medical Center
Collaborators
Pfizer
search

1. Study Identification

Unique Protocol Identification Number
NCT00441597
Brief Title
Does Atorvastatin Reduce Ischemia-Reperfusion Injury in Humans in-Vivo?
Official Title
Does Atorvastatin Reduce Ischemia-Reperfusion Injury in Humans in-Vivo?
Study Type
Interventional

2. Study Status

Record Verification Date
March 2009
Overall Recruitment Status
Completed
Study Start Date
February 2007 (undefined)
Primary Completion Date
February 2009 (Actual)
Study Completion Date
March 2009 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Radboud University Medical Center
Collaborators
Pfizer

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
To study the impact of 3 day exposure to atorvastatin 80mg on Annexin A5 targeting after ischemic exercise in the non-dominant forearm.
Detailed Description
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (also known as statins) have been found to reduce cardiovascular events. This protective effect has been traditionally explained by lowering plasma cholesterol and subsequent reduced progression of atherosclerosis. However in animal experiments statins have also shown the ability to induce pharmacologic preconditioning and thereby reduce infarct size. This effect contributes to the beneficial effect of statins on reducing of cardiovascular events. In order to differentiate between these two mechanisms of protection we will study the effect of atorvastatin on ischemia reperfusion damage after a short exposure to atorvastatin, before the lipid lowering effect of atorvastatin becomes apparent.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ischemia Reperfusion Injury, Cardiovascular Disease
Keywords
ischemia reperfusion injury, atorvastatine, preconditioning, cardiovascular disease

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Active Comparator
Arm Description
first 3 day treatment placebo and 4 weeks later three day treatment with atorvastatin 80 mg
Arm Title
2
Arm Type
Active Comparator
Arm Description
first 3 day treatment atorvastatin 80 mg and 4 weeks later three day treatment with placebo
Arm Title
3
Arm Type
No Intervention
Arm Description
3 days treatment with placebo twice
Intervention Type
Drug
Intervention Name(s)
atorvastatin
Other Intervention Name(s)
lipitor
Intervention Description
atorvastatine 80mg, during 3 days
Primary Outcome Measure Information:
Title
Annexin A 5 targeting in the non dominant thenar muscle after ischemic exercise, as a indicator for ischemia reperfusion injury.
Time Frame
60 and 240 minutes after ischemic exercise
Secondary Outcome Measure Information:
Title
workload during ischemic exercise
Time Frame
workload during 10minutes of ischemic exercise
Title
effect of 3-day treatment with atorvastatin 80mg daily on serum lipid levels
Time Frame
fasting lipid levels before and at first day after 3 day treatment with atorvastatin

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Male Age 18-50 years Informed consent Physical able to perform ischemic exercise Exclusion Criteria: History of any cardiovascular disease Hypertension (in supine position: systole > 140 mmHg, diastole > 90 mmHg) Diabetes mellitus (fasting glucose > 7.0 mmol/L or random glucose > 11.0 mmol/L) Hyperlipidaemia (fasting total cholesterol > 5.5 mmol/l) Alanine-Amino-Transferase (ALAT) >90 U/L Creatinine Kinase (CK) >440 U/L Drug or alcohol abuse Concommitant chronic use of medication Administration of radioactivity in research setting during the last 5 years Participation to any drug-investigation during the previous 60 days as checked with VIP check according to CRCN standard procedures
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gerard Rongen, MD PhD
Organizational Affiliation
RUMCN
Official's Role
Principal Investigator
Facility Information:
Facility Name
Radboud University Nijmegen Medical Centre
City
Nijmegen
ZIP/Postal Code
6500 HB
Country
Netherlands

12. IPD Sharing Statement

Citations:
PubMed Identifier
15623546
Citation
Rongen GA, Oyen WJ, Ramakers BP, Riksen NP, Boerman OC, Steinmetz N, Smits P. Annexin A5 scintigraphy of forearm as a novel in vivo model of skeletal muscle preconditioning in humans. Circulation. 2005 Jan 18;111(2):173-8. doi: 10.1161/01.CIR.0000151612.02223.F2. Epub 2004 Dec 27.
Results Reference
background
PubMed Identifier
15685892
Citation
Riksen NP, Smits P, Rongen GA. Ischaemic preconditioning: from molecular characterisation to clinical application--part II. Neth J Med. 2004 Dec;62(11):409-23.
Results Reference
background

Learn more about this trial

Does Atorvastatin Reduce Ischemia-Reperfusion Injury in Humans in-Vivo?

We'll reach out to this number within 24 hrs